ASX BRIEFS
Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.
ASX BRIEFS
INVION (IVX) - Pioneering Cancer Treatment Breakthroughs: Invion's Thian Chew discusses the Promise of Photosoft Technology and Upcoming Clinical Trials
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Unlock the potential of groundbreaking cancer treatments with Thian Chew, CEO of Invion, as he unveils the transformative power of Photosoft technology in our latest podcast. Discover how this revolutionary approach is meticulously designed to target and obliterate cancer cells while sparing the healthy ones. In this engaging session, Thian navigates us through Invion's journey from meticulous preclinical research to the pivotal moment of human trials, sharing the exhilaration of placing their innovations under the real-world microscope.
Thian not only sheds light on the intricacies of Photosoft technology but also takes us behind the scenes of Invion's strategic partnerships with leading research institutions, including the Hudson Institute of Medical Research and the Peter McCallum Cancer Centre. These alliances are not just endorsements of the promising tech; they're propelling Invion's mission with pivotal financial support. Get an insider look at the upcoming clinical trials poised to make waves in the treatment of non-melanoma skin cancer, inogenital cancers, and a yet-to-be-named solid tumor with substantial medical needs. This episode isn't just a conversation; it's a glimpse into a future where cancer may no longer be an invincible foe.
Welcome to another episode of ASX Briefs . I'm your host , Andrew Musgrave , and today we're speaking with Thian Chew , the CEO of Invion . Invion , is a trailblazer in the clinical stage life sciences sector , focusing on developing advanced therapies for the treatment of cancer and other serious diseases using their proprietary Photosoft technology . Thian , thanks for joining us today and welcome to the ASX Briefs podcast .
Thian ChewThanks Andrew , nice to meet you .
Andrew MusgraveI think we'll just start with a company overview . A lot of people may have not heard of Invion , so if you can just give us an overview of the company and tell us why this year is such an exciting period for Invion .
Thian ChewSo Invion is a clinical stage life sciences company . We have a technology called photodynamic therapy . It's actually classified under the broader trademark of photoshop technology and the reason its really exciting for us is were actually at a clinical trial stage inflection point . So we're going away from really stuff that you do in a lab or with mice and really getting into humans and really showing this technology works in human beings . The other reason it's really interesting for us is we've actually announced recently a number of partnerships where , in addition to validating our technology with folks , we're actually getting people to help fund some of our programs . So both sides I'm pretty excited about where it's heading .
Andrew MusgraveAnd I think just on the Photosoft technology . Can you just explain how it actually works and what makes it a promising treatment for cancers and other diseases ?
Thian ChewYeah , sure , Andrew . So Photosoft technology essentially's a drug or a compound which we have a topical as well as an IV formulation , so you put in your skin , you can inject it , and what happens is the compound selectively gets uptake , uptaken by cancer cells , but actually doesn't accumulate in healthy tissue . So that's kind of the first step . The second step is nothing happens until you shine a frequency of light . And because you actually only shine it on a targeted area and because it only accumulates in the cancer cells , then when the light is shone on those cells it creates what's known as reactive oxygen species , which essentially kills just the cancer cells . And that's the first mechanism of action . The second mechanism is because there are bits of you know , cancer cells floating around , the immune system starts recognizing the cancer itself and actually starts activating and fighting the cancers beyond just the ablation of the tumor .
Andrew MusgraveAnd with these programs at the moment you do have your clinical trials taking place . So can you tell us a bit more about what you're hoping to achieve with the upcoming phase one and two skin cancer trial and what other clinical trials you're planning ?
Thian ChewYeah , so the first clinical trial we're planning is the phase one and two non-melanoma skin cancer trial , and that really is aimed to test the safety as well as potential efficacy and dosing in treating most skin cancer about 98% of skin cancers and that's really the first step . For us , the new show works and works in a topical piece indication , like skin cancer . On the back of that we want to do more systemic and other more insidious cancers that are more life-threatening and that will include inogenital cancers , which we're planning to do with Peter Mack . They've been working with us to date on that space and we're also looking at doing a clinical trial in a solid tumor , which we haven't decided on yet , but it's going to be something that's got a pretty significant unmet medical need and one that will hopefully shake some trees out there .
Andrew MusgraveNow Invion has formed significant research partnerships , such as those with the Hudson Institute of Medical Research , the Peter McCallum Cancer Centre and the large South Korean pharmaceutical group , Hanlim . How do these collaborations enhance your research capabilities ?
Thian ChewYeah , well , I mean , as you know , in the life sciences space it's extremely specialized , and so we tend to partner up with institutes and firms that have this domain expertise .
Thian ChewAnd today a lot of that has been around purely the research side . So we've been working with the Hudson Institute of Medical Research , particularly on some buckets of concept preclinical work , and then more recently we've been working with the Peter McCallum Cancer Center , which , which is really one of the largest cancer-focused translation medicine centers in the world . They run about 500 clinical trials at any one time and so we've been working with them essentially to partner and leverage their expertise . Now , more recently , this has expanded . We announced quite recently that the Hanman Pharma , which is basically one of South Koreans of largest pharmaceutical groups , is partnering with us for two reasons . But one is actually to do some research , um in basically glioblastoma , which is a brain cancer , and the other thing that's , uh , very helpful for us is that they're also providing the funding for this , our research program . So we expect that the research collaborations will continue to expand as time goes on .
Andrew MusgraveOkay , and if we just look at future applications , aside from treating cancer , your technology is also aimed at addressing other diseases . What progress have you made in these areas ?
Thian ChewYeah , so cancer is our primary clinical focus , but we did actually do some work on infectious disease and actually found that our technology works on viruses , fungi and bacteria across the board , and so what we've done there is there's a couple of programs that we're spending some effort on , but not a lot of capital on . One of them is HPV virus , which is actually a precursor to many intergenital cancers , and we're working with a South Korean company called Dr INB who has experience in a modality of PDT . They're basically going to be running and funding all the research up to proof of concept clinical trials in gynecological hospitals in Korea . So that opens a whole new area , for HPV is the most common STD and it's very high prevalence , particularly in this part of the world . About 25% of women in Asia actually have it . The second area in infectious diseases is looking at periodontal space , particularly peri-implantitis . There's a lot of post-implant infections in leukocytes that occurs , and we believe that our technology can actually significantly reduce the incidence of those complications .
Andrew MusgraveAnd if we just look at the challenges but also the opportunities . First of all , what are some of the biggest challenges you face in the development and commercialisation of the Photosoft technology ?
Thian ChewWell , you know , I think from a research and clinical development perspective we're actually doing really well . We're just getting a lot of attention , a lot of people from the scientific community and the clinical community pretty interested in having discussions with us . Really , the two challenges I see going forward , number one would be , frankly , for the market to catch up with what we're doing . We've actually had some interesting announcements recently which we call were very interesting , but you know the market response just wasn't quite there , but you know that happens . The market is often unpredictable and as we just get more and more positive announcements out there , it'll eventually catch up .
Thian ChewI think , the second Go on .
Andrew MusgraveYeah , no , I was just going to say on the other side of the coin , what sort of opportunities are on the horizon ?
Thian ChewWell , you know , apart from the clinical trials , I think the opportunities are actually really , if you think about the inflection point for biotech company , it's when you've shown well , it shows cancer in mice , but really people are interested in the treatment for humans . That's the stage we're at now and so if you think about our valuation right now , it's really more value like a university spin-off than necessarily a clinical stage asset . So once we start getting this clinical data , then there could be some significant upside to where the stock is trading today . I think the other opportunities is as we're getting more traction with different partners . We're continuing to look at partnership opportunities with our current and potentially future partners and I think putting all of that together alongside a clinical state and selection point I think makes a pretty interesting time for us .
Andrew MusgraveNow , just to wrap things up , what are some of the key milestones you're looking to achieve in the next sort of 12 to 18 months ? Why should shareholders put Invion on their radar ?
Thian ChewWell , I guess if you want to add significant amount in terms of our return , it's about risk adjusted return . So right now , because of our inflection point , if you look at our valuation today at market cap , it is relatively low . If you compare it to other comparable multiple oncology assets which are at clinical trial stage , I think you'll see quite a fair bit of upside there and I think that's why it's really interesting . I mean , in terms of specific catalysts , we're looking to do more than one clinical trial and we'll start getting the data . Certainly some of the initial data should be out within the next 12 months and then we'll continue to look at our partnerships and opportunities for partnerships and we'll continue to further announce those and within those partnerships , as you have findings , we'll announce those .
Thian ChewSo there's actually quite a fair number of catalysts out there and it's a little bit of a change compared to the last couple of years . We've been really quiet because most of the work for the last couple of years was really essential but very uninteresting work to get safety , toxicity and regulatory requirements that the market generally doesn't care about . So we were pretty quiet because we had nothing to say . Now we're getting to the rather hit the road stage and we're pretty excited about the news flow and the potential coming up .
Andrew MusgraveAll right . Well , Thian , thanks for your time today and the insights into this exciting research , and we look forward to the next updates from Invion in the coming months . Great Thanks , Andrew . Great Thank you in the coming months .
Thian ChewGreat Thanks , Andrew .
Andrew MusgraveGreat Thank you . That concludes this episode of ASX Briefs . Don't forget to subscribe and we look forward to catching you on our next episode .